

REFERENCES

1. Nation LR, Samson NL. Bioequivalence requirements for generic products. *Pharmacol Ther* 1994; 62: 42-55.
2. Thai FDA, Ministry of Public Health, Thailand. Criteria and Guideline for the Bioequivalence Study of Generic Drugs. 2000.
3. Sauter R, Steinijans VW, Diletti E, Bohm A, Schultz HU. Presentation of results from bioequivalence studies. *Int J Clin Pharmacol Ther Toxicol* 1992; 30 (Suppl 1): 7-30.
4. George T. Cholinesterase inhibitors for the treatment of Alzheimer's Disease: getting on and staying on. *Curr Ther Res* 2003; 64(4): 216-35.
5. Guinther C. (2006). The treatment of Alzheimer's disease [Online]. Available at: <http://www.MyWalgreensCE.com> [2007, January 27]
6. Delagarza VW. Pharmacologic treatment of Alzheimer's disease: an update. *Clin Pharmacol* 2003; 68(7): 1365-72.
7. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. *JAMA* 1997; 278: 1363-71.
8. Nordeberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. *Drug Saf* 1998; 19: 465-80.
9. Blackard WG Jr, Sood GK, Crowe DR, Fallon MB. Tacrine. A cause of fatal hepatotoxicity? *J Clin Gastroenterol* 1998; 26: 57-9.
10. Physician's Desk Reference. 54th ed.: Medical economics. Montvale NJ 2000: 2323.

11. Jackson S, Ham RJ, Wiekinson D. The safety and tolerability of donepezil in patients with Alzheimer's disease. *Br J Clin Pharmacol* 2004; 58(Suppl 1): 1-8.
12. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the result of a US multicentre open label extension study. *Eur Neuropsychopharmacol* 1998; 8(1): 67-75.
13. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately and severely impaired renal function. *Br J Clin Pharmacol* 1998; 46 (Suppl 1): 56-60
14. Hachiro S, Yoshiharu Y, Youichi L, Yoshiyuki K. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. *Current Med Chem* 2000; 7: 303-339.
15. Aricept product monograph (Eisai—Canada), Rev 8/8/97, Rec 10/29/97.
16. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. *Br J Clin Pharmacol*. 1998; 46 (Suppl 1): 1-6.
17. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. *Clin Pharmacokinet* 2002; 41(10): 719-39.
18. Lu Y, Wen H, Li W, Chi Y, Zhang Z. Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application of pharmacokinetic studies in healthy, young, Chinese subjects. *J Chromatogr Sci* 2004; 42(5): 234-7.
19. Ohishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, Morishita N, Tanaka T. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. *J Clin Pharmacol*. 1993; 33(11): 1086-91.
20. Mihara M, Kamakura H, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, Morishita N. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteer. *Int J Clin Pharmacol Ther Toxicol* 1993; 31(5): 223-9.

21. Geldmacher DS. Donepezil (Aricept[®]) for the treatment of Alzheimer's disease and other dementing conditions. *Expert Rev Neurother* 2004; 4(1): 5-16.
22. Daniels CE. Donepezil (Aricept[®]): A brief review. *Pharmacy Update* 1998.
23. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of ¹⁴C donepezil in healthy volunteers: a single dose study. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 19-24.
24. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 25-9.
25. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 30-4.
26. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-doses administration in healthy volunteers. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 35-9.
27. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and dioxin: assessment of pharmacokinetic changes. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 40-4.
28. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple dose of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 45-50.
29. Tiseo PJ, Vargas R, Perdomo CA, et al. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. *Br J Clin Pharmacol* 1998; 46(Suppl 1): 51-5.
30. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. *Clin Pharmacokinetic* 2002; 41: 719-39.
31. Yasui-Furukori N, Furuya R, Takahata T. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid

- chromatography with ultraviolet absorbance detection. *J Chromatogr Sci B* 768 2002; 261-5.
32. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. *Dementia* 1996; 7: 293-303.
 33. Sugimoto H, Tsuchiya Y, Sugumi H, Higurashi K, Karibe N, Limura Y, Sasaki A, Kawakami Y, Nakamura T, Araki S, Yamanishi Y, Yamatsu K. New cholinesterase inhibitors: synthesis and structure-activity relationship studies of 1,2-benzisoxazole series and novel imidazolyl-d²-isoxazolines. *J Med Chem* 1990; 33: 1880.
 34. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology* 1998; 50: 136-45.
 35. Homma A, Imai Y, Hagiguchi S, Kameyama M, Nishimaru T. Late Phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia. *Clin. Eval* 1998; 26: 251-284.
 36. Radwan M, Abdine H, Al-Quadeb B, Aboul-Enein H, Nakashima K. Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. *J Chromatogr Sci B* 830 2006; 114-9.
 37. Nakashima K, Itoh K, Kono M, Nakashima M, Wada M. Determination of donepezil hydrochloride in human and rat plasma, blood and brain microdialysates by HPLC with a short C30 column. *J Pharm Biomed Anal* 2006; 41: 201-6.
 38. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's disease. *Arch Intern Med* 1998; 158: 1021-31.
 39. Hao XY, Ding L, Li LM, Bian XJ, Zhang SQ. Bioequivalence of donepezil capsule and tablet in human. *Yao Xue Xue Bao* 2003; 38(5): 392-4.